TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS

American Journal of Translational Research

Michael Goldblatt¹  Michael Kinch¹  Yu Zhou¹  David Santos¹  Josephine Cassella¹  Leyla Diaz¹  Hanson Chen¹  Manu Kohli¹  James D Marks¹  Hanwen Mao¹  Zena Fesseha¹  Ke Weng¹  Douty Bamba¹ 

关键词: TSG101;    HIV;    monoclonal antibody;    CB8-2;    HIV/AIDS therapy;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

HIV infection remains a major global public health problem, in part because of the ability of the virus to elude antiretroviral therapies. Most conventional drugs were designed to directly target virus-encoded mechanisms. However, there is increasing appreciation that certain host-encoded molecules are comparably important for the viral life cycle and could therefore represent potential antiviral targets. Prominent among these is TSG101, a cytoplasmic molecule that is “hijacked” by HIV and used to facilitate viral budding and release. In our present report, we demonstrate thatTSG101 is uniquely exposed on the surface of HIV-infected cells and is available to antibody-based therapies. We also characterize the development of a monoclonal antibody, CB8-2, which reduces virus production from infected cells. These studies demonstrate the potential of TSG101-directed antibodies to combat HIV/AIDS.

【 授权许可】

Unknown